Value Proposition Revenue Model

Pre-commercial revenue base: OKYO appears to have no meaningful operating revenue, so value capture remains dependent on future clinical or financing milestones.

Single-asset biotech economics: A development-stage model concentrates value creation in pipeline success, which makes revenue timing and magnitude highly uncertain versus diversified biopharma peers.

No recurring monetization structure: The absence of product sales, licensing scale, or service revenue limits near-term revenue visibility and reduces model repeatability.

Cost Structure

R&D-light current spend profile: Reported R&D-to-revenue is zero because revenue is absent, indicating costs are not yet supported by operating inflows.

Fixed public-company overhead: Administrative and listing costs create a persistent cash burden that is structurally heavy relative to a pre-revenue base.

Low capital intensity today: Capex is negligible, but that reflects an asset-light development model rather than a cost advantage over commercial-stage peers.

Scalability Operating Leverage

Limited operating leverage until commercialization: Without product revenue, incremental scale does not yet translate into margin expansion or operating leverage.

Binary scaling path: Scaling depends on clinical progression and regulatory conversion, which creates stepwise rather than smooth growth versus platform peers.

No manufacturing or distribution leverage: The current model lacks the repeatable unit economics that typically drive scalable margin expansion in commercial biotech.

Customer Structure Concentration

No diversified customer base: With no commercial sales, the company has no broad customer mix to stabilize demand or reduce concentration risk.

Capital-provider dependence: Value capture is effectively concentrated in equity and financing markets, making the business model more dependent on external funding than customers.

Peer-relative concentration risk: Compared with approved-drug peers, OKYO has materially higher concentration because a single development path dominates future value.

Revenue Quality Predictability

Low revenue visibility: The model lacks recurring revenue streams, so predictability is materially weaker than commercial-stage biotech peers.

Milestone-driven cash generation: Future inflows, if any, are likely tied to clinical or partnering events, which are inherently lumpy and hard to forecast.

Income quality not yet durable: FMP income quality is not enough to offset the absence of operating revenue, so cash generation remains structurally fragile.

Overall Score

OKYO’s business model is anchored by a pre-commercial biotech structure that can create upside if development succeeds, but it currently lacks recurring revenue, operating leverage, and predictable cash generation.

Score Driver: The Dominant Driver Is A Pre-Revenue, Milestone-Dependent Model That Severely Limits Scalability And Predictability Versus Commercial-Stage Peers.